BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Pieris Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-08-17 4:49 pm Unchanged |
2023-08-10 | 13D | Pieris Pharmaceuticals, Inc. PIRS |
BIOTECHNOLOGY VALUE FUND L P | 257,623 20.800% |
0 (Unchanged) |
Filing |
| 2023-05-22 4:47 pm Purchase |
2023-05-11 | 13D | Pieris Pharmaceuticals, Inc. PIRS |
BIOTECHNOLOGY VALUE FUND L P | 257,623 22.000% |
161,448 (+167.87%) |
Filing |
| 2023-02-13 8:14 pm Purchase |
2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
BIOTECHNOLOGY VALUE FUND L P | 96,176 9.990% |
3,593 (+3.88%) |
Filing |
| 2022-02-14 1:56 pm Purchase |
2021-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
BIOTECHNOLOGY VALUE FUND L P | 92,583 9.990% |
22,563 (+32.22%) |
Filing |
| 2021-02-12 4:20 pm Sale |
2020-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
BIOTECHNOLOGY VALUE FUND L P | 70,020 9.990% |
-3,390 (-4.62%) |
Filing |